Joshua Elkington
@elkington.bsky.social
Let the Best Drug Win with Errik Anderson axial.substack.com/p/let-the-be...
Errik Anderson is the CEO and Founder of Alloy Therapeutics. Founded in 2017, the company democratizes access to drug discovery platforms and services. In our conversation, we discuss Alloy's product offering and story
Errik Anderson is the CEO and Founder of Alloy Therapeutics. Founded in 2017, the company democratizes access to drug discovery platforms and services. In our conversation, we discuss Alloy's product offering and story
January 4, 2024 at 6:29 PM
Let the Best Drug Win with Errik Anderson axial.substack.com/p/let-the-be...
Errik Anderson is the CEO and Founder of Alloy Therapeutics. Founded in 2017, the company democratizes access to drug discovery platforms and services. In our conversation, we discuss Alloy's product offering and story
Errik Anderson is the CEO and Founder of Alloy Therapeutics. Founded in 2017, the company democratizes access to drug discovery platforms and services. In our conversation, we discuss Alloy's product offering and story
Alexion helped pioneer the rare disease business model. Their business was enabled by new technology (recombinant biology), new regulations (Orphan Drug Act), and better ways to acquire patients (close partnership with Leeds Hospital) axial.substack.com/p/axial-alex...
October 31, 2023 at 2:36 PM
Alexion helped pioneer the rare disease business model. Their business was enabled by new technology (recombinant biology), new regulations (Orphan Drug Act), and better ways to acquire patients (close partnership with Leeds Hospital) axial.substack.com/p/axial-alex...
Veeva axial.substack.com/p/axial-veeva
Veeva was founded in 2007 by Peter Gassner and Matt Wallach to make life sciences more efficient and bring new medicines to patients. The company is one of the most important case studies on how to build a standalone software business in life sciences.
Veeva was founded in 2007 by Peter Gassner and Matt Wallach to make life sciences more efficient and bring new medicines to patients. The company is one of the most important case studies on how to build a standalone software business in life sciences.
October 30, 2023 at 2:04 PM
Veeva axial.substack.com/p/axial-veeva
Veeva was founded in 2007 by Peter Gassner and Matt Wallach to make life sciences more efficient and bring new medicines to patients. The company is one of the most important case studies on how to build a standalone software business in life sciences.
Veeva was founded in 2007 by Peter Gassner and Matt Wallach to make life sciences more efficient and bring new medicines to patients. The company is one of the most important case studies on how to build a standalone software business in life sciences.
Drugs that are their own pipelines axial.substack.com/p/drugs-that...
October 29, 2023 at 3:50 PM
Drugs that are their own pipelines axial.substack.com/p/drugs-that...
BridgeBio axial.substack.com/p/axial-brid...
October 26, 2023 at 11:14 PM
BridgeBio axial.substack.com/p/axial-brid...
Scientist Stories: Terry Orr-Weaver, Cell Division and Chromosome Segregation youtu.be/4OHiHK4GlSE
September 28, 2023 at 5:34 PM
Scientist Stories: Terry Orr-Weaver, Cell Division and Chromosome Segregation youtu.be/4OHiHK4GlSE
Scientist Stories: Sonja Schrepfer, The Future of Stem Cells and Hypoimmune Cell Therapies youtu.be/6sthpRhMZhg
September 20, 2023 at 4:37 PM
Scientist Stories: Sonja Schrepfer, The Future of Stem Cells and Hypoimmune Cell Therapies youtu.be/6sthpRhMZhg
Modular cytokine receptor-targeting chimeras for targeted degradation of cell surface and extracellular proteins www.nature.com/articles/s41...
September 19, 2023 at 4:43 PM
Modular cytokine receptor-targeting chimeras for targeted degradation of cell surface and extracellular proteins www.nature.com/articles/s41...
Deep Visual Proteomics defines single-cell identity and heterogeneity www.nature.com/articles/s41...
September 15, 2023 at 4:34 PM
Deep Visual Proteomics defines single-cell identity and heterogeneity www.nature.com/articles/s41...
Founder Stories: Tassos Gianakakos, CEO of MyoKardia youtu.be/Haa6ORz__ig
September 14, 2023 at 5:16 PM
Founder Stories: Tassos Gianakakos, CEO of MyoKardia youtu.be/Haa6ORz__ig
The human disease gene LYSET is essential for lysosomal enzyme transport and viral infection www.science.org/doi/10.1126/...
September 13, 2023 at 8:49 PM
The human disease gene LYSET is essential for lysosomal enzyme transport and viral infection www.science.org/doi/10.1126/...
"It's not enough what I did in the past - there is also the future"
- Rita Levi-Montalcini, Nobel Prize winner for discovering nerve growth factor
- Rita Levi-Montalcini, Nobel Prize winner for discovering nerve growth factor
September 13, 2023 at 3:57 AM
"It's not enough what I did in the past - there is also the future"
- Rita Levi-Montalcini, Nobel Prize winner for discovering nerve growth factor
- Rita Levi-Montalcini, Nobel Prize winner for discovering nerve growth factor
KRAS is vulnerable to reversible switch-II pocket engagement in cells www.nature.com/articles/s41...
September 12, 2023 at 3:40 PM
KRAS is vulnerable to reversible switch-II pocket engagement in cells www.nature.com/articles/s41...
"We believe that the last person in the door is just as important as the first. We consciously reject the German model for the Silicon Valley model. We want the guy on the loading dock to be thinking about clinical programs."
- Joshua Boger, Founder & CEO of Vertex Pharmaceuticals
- Joshua Boger, Founder & CEO of Vertex Pharmaceuticals
September 11, 2023 at 11:13 PM
"We believe that the last person in the door is just as important as the first. We consciously reject the German model for the Silicon Valley model. We want the guy on the loading dock to be thinking about clinical programs."
- Joshua Boger, Founder & CEO of Vertex Pharmaceuticals
- Joshua Boger, Founder & CEO of Vertex Pharmaceuticals
Founder Stories: Joshua Boger, Founder and CEO of Vertex Pharmaceuticals youtu.be/DdKVhpZ9Q4k
September 11, 2023 at 3:45 PM
Founder Stories: Joshua Boger, Founder and CEO of Vertex Pharmaceuticals youtu.be/DdKVhpZ9Q4k
Human chimeric antigen receptor macrophages for cancer immunotherapy www.nature.com/articles/s41...
September 10, 2023 at 4:45 PM
Human chimeric antigen receptor macrophages for cancer immunotherapy www.nature.com/articles/s41...
Worth a Read: 'Unexpected Effects of Protein Degradation' www.science.org/content/blog...
September 7, 2023 at 10:00 PM
Worth a Read: 'Unexpected Effects of Protein Degradation' www.science.org/content/blog...
Accelerating high-throughput virtual screening through molecular pool-based active learning pubs.rsc.org/en/content/a...
Applying Bayesian optimization to the problem of HTS by constructing a surrogate model of the docking score of a ligand for a given protein target
Applying Bayesian optimization to the problem of HTS by constructing a surrogate model of the docking score of a ligand for a given protein target
September 7, 2023 at 7:26 PM
Accelerating high-throughput virtual screening through molecular pool-based active learning pubs.rsc.org/en/content/a...
Applying Bayesian optimization to the problem of HTS by constructing a surrogate model of the docking score of a ligand for a given protein target
Applying Bayesian optimization to the problem of HTS by constructing a surrogate model of the docking score of a ligand for a given protein target
Clonal fate mapping quantifies the number of haematopoietic stem cells that arise during development www.nature.com/articles/ncb...
With 2 approaches, the paper estimates that there are approximately 30 HSC clones that arise during development in zebrafish. Similar to estimates in other animals
With 2 approaches, the paper estimates that there are approximately 30 HSC clones that arise during development in zebrafish. Similar to estimates in other animals
September 5, 2023 at 4:45 PM
Clonal fate mapping quantifies the number of haematopoietic stem cells that arise during development www.nature.com/articles/ncb...
With 2 approaches, the paper estimates that there are approximately 30 HSC clones that arise during development in zebrafish. Similar to estimates in other animals
With 2 approaches, the paper estimates that there are approximately 30 HSC clones that arise during development in zebrafish. Similar to estimates in other animals
The N6-methyladenosine (m6A)-forming enzyme METTL3 controls myeloid differentiation of normal and leukemia cells www.nature.com/articles/nm....
September 4, 2023 at 3:46 PM
The N6-methyladenosine (m6A)-forming enzyme METTL3 controls myeloid differentiation of normal and leukemia cells www.nature.com/articles/nm....
The Neuronal Gene Arc Encodes a Repurposed Retrotransposon Gag Protein that Mediates Intercellular RNA Transfer www.cell.com/cell/pdf/S00...
September 3, 2023 at 3:46 PM
The Neuronal Gene Arc Encodes a Repurposed Retrotransposon Gag Protein that Mediates Intercellular RNA Transfer www.cell.com/cell/pdf/S00...
Global profiling of phosphorylation-dependent changes in cysteine reactivity www.nature.com/articles/s41...
The paper studies how phosphorylation of proteins affects the reactivity of cysteine residues
The paper studies how phosphorylation of proteins affects the reactivity of cysteine residues
September 1, 2023 at 5:24 PM
Global profiling of phosphorylation-dependent changes in cysteine reactivity www.nature.com/articles/s41...
The paper studies how phosphorylation of proteins affects the reactivity of cysteine residues
The paper studies how phosphorylation of proteins affects the reactivity of cysteine residues
Scientist Stories: Magdalena Zernicka-Goetz, Human Development and Synthetic Embryos youtu.be/2_cjdLb7adg
August 31, 2023 at 5:55 PM
Scientist Stories: Magdalena Zernicka-Goetz, Human Development and Synthetic Embryos youtu.be/2_cjdLb7adg
www.pnas.org/doi/abs/10.1... The paper introduces Botryllus schlosseri, a marine colonial chordate, as a model organism for the study of neurodegeneration. As well as the evolutionary origins of these processes
August 30, 2023 at 4:03 PM
www.pnas.org/doi/abs/10.1... The paper introduces Botryllus schlosseri, a marine colonial chordate, as a model organism for the study of neurodegeneration. As well as the evolutionary origins of these processes
Regulated Induced Proximity Targeting Chimeras (RIPTACs): a Novel Heterobifunctional Small Molecule Therapeutic Strategy for Killing Cancer Cells Selectively www.biorxiv.org/content/10.1...
August 29, 2023 at 3:50 PM
Regulated Induced Proximity Targeting Chimeras (RIPTACs): a Novel Heterobifunctional Small Molecule Therapeutic Strategy for Killing Cancer Cells Selectively www.biorxiv.org/content/10.1...